title: [Prevention of phlebitis caused by vinorelbine chemotherapy in outpatients with breast cancer].
abstract: We studied the prevention of phlebitis in 10 patients who had developed the symptoms after receiving vinorelbine to treat breast cancer at our outpatient chemotherapy clinic from July 2005 to August 2006. Veins proximal to the injection site were warmed using hot compresses during the vinorelbine injection and physiological saline was increased to wash out the drug after the injection from 250 mL to 500 mL in combination to investigate whether the treatment was effective in preventing phlebitis. The severity of phlebitis was significantly decreased after the combined treatment compared with the pre-treatment level (p=0.039). The combination was effective to relieve vascular pain during the injection in all 10 patients, and the number of event occurrences was significantly decreased (p<0.0005). It was also effective to decrease the frequency of vascular pain after patients returned home (p=0.001). The combination of hot compresses and increase of physiological saline for washing out was an effective treatment to prevent phlebitis caused by vinorelbine. The comparison of patient characteristics to find other contributing factors to phlebitis than vinorelbine revealed no association with the number of doses, diameter of the vein to be punctured, or pretreatment.
authors.affiliation: Dept. of Nursing, Koshigaya Hospital, Dokkyo Medical University.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yokota
authors.forename: Tomoko
authors.initials: T
authors.lastname: Suzuki
authors.forename: Takeshi
authors.initials: T
authors.lastname: Narahashi
authors.forename: Jun
authors.initials: J
authors.lastname: Takizawa
authors.forename: Makoto
authors.initials: M
authors.lastname: Kojima
authors.forename: Retsu
authors.initials: R
authors.lastname: Shimada
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D010045:Outpatients; D010689:Phlebitis / Q000517:prevention & control*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine